These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 15311106)

  • 1. Ambulatory blood pressure reduction after rosiglitazone treatment in patients with type 2 diabetes and hypertension correlates with insulin sensitivity increase.
    Sarafidis PA; Lasaridis AN; Nilsson PM; Pagkalos EM; Hitoglou-Makedou AD; Pliakos CI; Kazakos KA; Yovos JG; Zebekakis PE; Tziolas IM; Tourkantonis AN
    J Hypertens; 2004 Sep; 22(9):1769-77. PubMed ID: 15311106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: a randomized controlled trial (the RECORD study).
    Komajda M; Curtis P; Hanefeld M; Beck-Nielsen H; Pocock SJ; Zambanini A; Jones NP; Gomis R; Home PD;
    Cardiovasc Diabetol; 2008 Apr; 7():10. PubMed ID: 18435852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of rosiglitazone on urine albumin excretion in patients with type 2 diabetes mellitus and hypertension.
    Sarafidis PA; Lasaridis AN; Nilsson PM; Hitoglou-Makedou AD; Pagkalos EM; Yovos JG; Pliakos CI; Tourkantonis AA
    Am J Hypertens; 2005 Feb; 18(2 Pt 1):227-34. PubMed ID: 15752951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients.
    Raji A; Seely EW; Bekins SA; Williams GH; Simonson DC
    Diabetes Care; 2003 Jan; 26(1):172-8. PubMed ID: 12502676
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of glargine insulin versus rosiglitazone addition in poorly controlled type 2 diabetic patients on metformin plus sulfonylurea.
    Triplitt C; Glass L; Miyazaki Y; Wajcberg E; Gastaldelli A; De Filippis E; Cersosimo E; DeFronzo RA
    Diabetes Care; 2006 Nov; 29(11):2371-7. PubMed ID: 17065670
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rosiglitazone effects on blood pressure and metabolic parameters in nondipper diabetic patients.
    Negro R; Mangieri T; Dazzi D; Pezzarossa A; Hassan H
    Diabetes Res Clin Pract; 2005 Oct; 70(1):20-5. PubMed ID: 16126119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rosiglitazone reduces office and diastolic ambulatory blood pressure following 1-year treatment in non-diabetic subjects with insulin resistance.
    Nilsson PM; Hedblad B; Donaldson J; Berglund G
    Blood Press; 2007; 16(2):95-100. PubMed ID: 17612907
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of rosiglitazone/metformin fixed-dose combination therapy and metformin monotherapy on serum vaspin, adiponectin and IL-6 levels in drug-naïve patients with type 2 diabetes.
    Kadoglou NP; Kapelouzou A; Tsanikidis H; Vitta I; Liapis CD; Sailer N
    Exp Clin Endocrinol Diabetes; 2011 Feb; 119(2):63-8. PubMed ID: 21031343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rosiglitazone improves insulin sensitivity, glucose tolerance and ambulatory blood pressure in subjects with impaired glucose tolerance.
    Bennett SM; Agrawal A; Elasha H; Heise M; Jones NP; Walker M; Wilding JP
    Diabet Med; 2004 May; 21(5):415-22. PubMed ID: 15089784
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of rosiglitazone on novel atherosclerotic risk factors in patients with type 2 diabetes mellitus and hypertension. An open-label observational study.
    Sarafidis PA; Lasaridis AN; Nilsson PM; Mouslech TF; Hitoglou-Makedou AD; Stafylas PC; Kazakos KA; Yovos JG; Tourkantonis AA
    Metabolism; 2005 Sep; 54(9):1236-42. PubMed ID: 16125536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pioglitazone reduces blood pressure in non-dipping diabetic patients.
    Negro R; Dazzi D; Hassan H; Pezzarossa A
    Minerva Endocrinol; 2004 Mar; 29(1):11-7. PubMed ID: 15258553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pioglitazone shift circadian rhythm of blood pressure from non-dipper to dipper type in type 2 diabetes mellitus.
    Anan F; Masaki T; Fukunaga N; Teshima Y; Iwao T; Kaneda K; Umeno Y; Okada K; Wakasugi K; Yonemochi H; Eshima N; Saikawa T; Yoshimatsu H
    Eur J Clin Invest; 2007 Sep; 37(9):709-14. PubMed ID: 17696960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rosiglitazone improves, while Glibenclamide worsens blood pressure control in treated hypertensive diabetic and dyslipidemic subjects via modulation of insulin resistance and sympathetic activity.
    Yosefy C; Magen E; Kiselevich A; Priluk R; London D; Volchek L; Viskoper RJ
    J Cardiovasc Pharmacol; 2004 Aug; 44(2):215-22. PubMed ID: 15243303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of insulin sensitivity treatment with pioglitazone on endothelial function in non-diabetic patients with arterial hypertension.
    Schneider F; Vossler S; Franke S; Bär F; Konrad T
    Int J Clin Pharmacol Ther; 2009 May; 47(5):311-20. PubMed ID: 19473593
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of American ginseng (Panax quinquefolius L.) on arterial stiffness in subjects with type-2 diabetes and concomitant hypertension.
    Mucalo I; Jovanovski E; Rahelić D; Božikov V; Romić Z; Vuksan V
    J Ethnopharmacol; 2013 Oct; 150(1):148-53. PubMed ID: 23973636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of an olmesartan medoxomil-based treatment algorithm in patients with hypertension and type 2 diabetes: analysis of diurnal blood pressure control as assessed by 24-hour ambulatory blood pressure monitoring.
    Kereiakes DJ; Neutel J
    Ther Adv Cardiovasc Dis; 2010 Oct; 4(5):285-93. PubMed ID: 20801941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pioglitazone decreases ambulatory blood pressure in type 2 diabetics with difficult-to-control hypertension.
    de Rivas B; Luque M; Martell N; Fernández C; Fernández-Cruz A
    J Clin Hypertens (Greenwich); 2007 Jul; 9(7):530-7. PubMed ID: 17617763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effect of combination antihypertensive therapy on circadian blood pressure and metabolic parameters in patients with type 2 diabetes mellitus].
    Statsenko ME; Derevianchenko MV; Pastukhova OR
    Kardiologiia; 2014; 54(11):20-4. PubMed ID: 25902654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rosiglitazone improves downstream insulin receptor signaling in type 2 diabetic patients.
    Miyazaki Y; He H; Mandarino LJ; DeFronzo RA
    Diabetes; 2003 Aug; 52(8):1943-50. PubMed ID: 12882909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment with rosiglitazone reduces hyperinsulinemia and improves arterial elasticity in patients with type 2 diabetes mellitus.
    Shargorodsky M; Wainstein J; Gavish D; Leibovitz E; Matas Z; Zimlichman R
    Am J Hypertens; 2003 Aug; 16(8):617-22. PubMed ID: 12878365
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.